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Abstract. A workshop took place in 2015 to follow up TREAT-NMD activities dedicated to improving quality in the preclinical
phase of drug development for neuromuscular diseases. In particular, this workshop adressed necessary future steps regarding
common standard experimental protocols and the issue of improving the translatability of preclinical efficacy studies.
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BACKGROUND
Since 2007, TREAT-NMD has played a major
role in accelerating research and moving more effec-
tive treatments towards the clinic for neuromuscular
diseases. At the preclinical level, TREAT-NMD
∗Correspondence to: Raffaella Willmann, Swiss Foundation for
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gelbergstrasse 50/70, CH-4056 Basel, Switzerland. Tel.: +41 77
4141002; E-mail: raffaella.willmann@unibas.ch.
previously developed several standardized oper-
ating procedures (SOPs), in collaboration with
the Wellstone Muscular Dystrophy Cooperative
Research Centers and leading scientists, to improve
reproducibility of research data [1, 2]. Several rec-
ommended guidelines were published to facilitate
best practice in preclinical work with the mdx mouse
model of Duchenne muscular dystrophy (DMD)
[3–5]. Following this, a dedicated committee for
expert evaluation of preclinical approaches and
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clinical plans (TREAT-NMD Advisory Commit-
tee for Therapeutics; TACT), established to ensure
translation to clinical trials, was set up as an inde-
pendent service for academic researchers, clinicians,
patient groups and industry. At this stage, a specific
workshop was required to (1) discuss the need for
additional SOPs for preclinical research in relation
to outcome measures used in clinical trials as well as
the natural advancement of methodologies; (2) estab-
lish rules for the external submission and acceptance
of SOPs; and (3) improve awareness concerning the
importance and relevance of preclinical study qual-
ity for neuromuscular diseases. A small focus group
of 11 participants met to discuss these issues and the
main outcomes are presented herein. As more than
2 years have elapsed since this Workshop, some sig-
nificant actions that have already resulted are also
included in this report.
PARTICIPANT PRESENTATIONS
Raffaella Willmann welcomed participants and
apologised on behalf of Annamaria De Luca and
Markus Ru¨egg, who were unable to attend due to
short-term commitments but were actively involved
in the preparation of the workshop while ensuring
their input in the follow up.
CLINICAL OUTCOME MEASURES
Anna Mayhew presented current clinician rated
outcomes used in clinical trials. In ambulant DMD
patients, the 6-minute-walk-test (6MWT) is still the
most widely used primary endpoint [6]. Secondary
outcomes include: myometry as a measure of mus-
cle strength, North Star Ambulatory Assessment
(NSAA) as a measure of motor performance [7, 8],
timed tests such as rise from floor, 10 metre walk/run,
climb and descend four stairs and respiratory mea-
sures such as forced vital capacity (FVC). Efforts
have been made in the UK and Italy to correlate the
total score on the NSAA with patient pathology and
there is intent to do this in other databases too [9].
One of the challenges is to understand the nonlin-
ear relationship between strength and function. For
non-ambulatory DMD patients there is an increasing
focus on assessing upper limb function. The Perfor-
mance of Upper Limb scale (PUL 1.2 and PUL 2.0)
has been developed to specifically assess this and
is under further development [10]. Patient Reported
Outcome Measures (PROMs) are also becoming
increasingly important to regulatory authorities as
they assess the impact of the disease on home and
family life. A specific module has been designed
for assessing arm function in DMD (PROM-Upper
for DMD [11]). Quality controls of the assessments
are carried out to ensure reliability across differ-
ent centres. It is evident that reliable results can
be obtained with all these measures. These efforts
were done using an active dialogue with patients and
regulators [12].
For spinal muscular atrophy (SMA), many
clinician-rated outcomes exist for all levels of abil-
ity (Type I, II and III), although not all of these
were specifically designed for SMA. The Children’s
Hospital of Philadelphia Infant Test of Neuromuscu-
lar Disorders (CHOP-INTEND) is suitable for Type
I infants [13]. There are international efforts in place
to revise the Hammersmith Functional Motor Scale
(HFMS – designed for use in Type II [14]) and its
expanded counterpart for ambulant patients (HFMSE
– for type II and III) into a more psychometrically
robust measure –the Revised Hammersmith Scale
(RHS) [15]. For arm function, there is a Revised
Upper Limb Module (RULM) [16]. Other tests used
are the Motor Function Measure (MFM), a more
generic functional assessment for neuromuscular
disease [17], and 6MWT which has been shown
to measure fatigue in SMA [18]. Strength may be
assessed in this group with very sensitive devices
such as the myopinch. Activity monitors may also
be useful and now exist for ambulatory and non-
ambulatory patients. In this group, the relationship
between function, fatigue and growth is an issue but
ultimately patient reported measures are paramount.
ANIMAL MODELS
Joe Kornegay discussed available dog models for
DMD and their mutations [19]. The golden retriever
muscular dystrophy (GRMD) model remains the
most used canine clinical model [20]: affected dogs
tend to show a progressive phenotype but some have
a relatively mild course more in keeping with Becker
muscular dystrophy (BMD) [21]. The Labrador and
Japanese Spitz show similar mild BMD syndromes
and DMD gene mutations have more recently been
described [22]. Interestingly, the German Shorthaired
Pointer-Muscular Dystrophy Dog (GSHPMD) has
essentially a spontaneous deletion of the entire DMD
M. van Putten et al. / Preclinical Research for DMD and SMA 31
gene with no dystrophin and also no revertant fibers
[23], offering a cleaner model for studying the
immunologic response to dystrophin as a neoanti-
gen. He emphasized the importance of themdxmouse
model as an initial screening tool to detect poten-
tial treatment efficacies, and the more pronounced
phenotype and relevance of dog models to the DMD
phenotype. As with DMD patients, phenotypic varia-
tion occurs in GRMD. This can potentially confound
preclinical studies, necessitating larger group sizes
to prove efficacy. Phenotypic variation can be coun-
tered by comparing longitudinal effects of treatment
and by balancing disease severity between treatment
and control groups. On the other hand, the presence
of phenotypic variation allows for studies to identify
genetic mechanisms that may contribute to so-called
“secondary effects” of dystrophin deficiency.
Gender of GRMD dogs, e.g. homozygous females
or heterozygous males, should also be considered in
preclinical studies [24], given that mdx females can
have a slightly less severe phenotype than males,
presumably due to effects of estrogen [25]. However,
for biomarkers commonly used in the Kornegay
laboratory, there was no observed effect of gender
[26]. It is important to bear in mind the man-dog age
relationship, which differs among canine breeds. For
example, larger breeds typically have shorter life
spans so each year equates to a greater number of
human years. For the golden retriever, the first year
of life corresponds to the first 20 years in humans
[27]. In this way, the course of GRMD over the first
year and DMD over the first 20 years can be divided
into quartiles, with 0–3, 3–6, 6–9, and 9–12 months
corresponding to 0–5, 5–10, 10–15, and 15–20 years
in DMD, respectively. This analogy is reasonably
accurate over the first 6 months in GRMD (10 years
of DMD), when both conditions progress at a similar
rate. However, many GRMD dogs stabilize between
6 and 12 months of age, whereas DMD continues to
progress. The rapid clinical progression of GRMD
between 3 and 6 months of age (5–10 years of DMD)
provides a relatively short window over which
therapeutic efficacy can be tested. Joe mentioned the
current SOPs available on the TREAT-NMD website
(http://www.treat-nmd.eu/research/preclinical/dmd-
sops/) and the opportunity to develop additional
SOPs for tests such as the 6MWT, gait analysis,
accelerometry, respiratory assessment (pneumotach,
respiratory inductance plethysmography (RIP)),
and cardiac assessment (electrocardiography, echo,
magnetic resonance imaging).
TREAT-NMD ADVISORY COMMITTEE
FOR THERAPEUTICS (TACT)
Kanneboyina Nagaraju presented the recent expe-
rience of TACT applications [28]. Many applicants
were considered to have submitted very preliminary
preclinical results with poor experimental design,
but claimed efficacy as soon as a minimal signifi-
cant difference was observed for a single outcome.
The sample size was sometimes not considered to be
adequate. This makes it difficult to interpret results.
The majority of the TACT applicants (especially
small companies) do not know about the exis-
tence of the TREAT-NMD SOPs (http://www.treat-
nmd.eu/research/preclinical/dmd-sops/).
CURRENT CHALLENGES
Shin‘ichi Takeda noted that another important
issue is the mouse age chosen for experimenta-
tions and suggested that tests in multiple domains
(i.e. muscle function, muscle strength, histology etc.)
should be required for each efficacy study on mdx
mice, as described in earlier review articles [4, 29].
Importantly, the ongoing studies on natural history
and clinician rated outcomes in DMD patients and
the discussion around the canine models, corroborate
the need to upgrade SOPs for mdx mice, in order to
have more translatable readouts. Also, it is underlined
that novel methodological approaches have been pro-
posed by various groups to be included in SOPs for
mdxmice as possibly important correlates of clinician
rated outcomes. Consensus about which procedures
to validate and include as new SOPs is then needed.
Annemieke Aartsma-Rus mentioned an open letter
to journal editors available under http://www.treat-
nmd.eu/resources/ethics/open-letter/ that emphasises
the danger of highlighting potential efficacy of drugs
using poor or not rigorously reproduced experimental
evidence, because this leads some families to pur-
chase products privately on the basis of such hope.
She underlined the high need to distinguish between
exploratory ‘proof of principle’ animal studies and
confirmatory pre-clinical trials and to require stronger
rigor for the latter.
Tom Gillingwater referred to a wide variability of
pre-clinical results reported by the SMA research
community, likely resulting from the use of sev-
eral different mouse models presenting with different
degrees of pathology. This also raised issues concern-
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ing the relevance of current SMA mouse models to
different SMA types in patients. Based on the exten-
sive variability observed between mouse models, he
considered it unfeasible at present to propose a list of
obligatory tests in preclinical studies for SMA. How-
ever, standards for reporting experimental details and
conditions (including handling, feeding etc.) which
could influence outcomes will be useful. In addi-
tion, the issue of treatments being efficacious in SMA
models only if delivered pre-symptomatically, raises
issues concerning applicability to patients.
DISCUSSIONS
There was extensive discussion on three main
topics.
SOPs and guidelines for preclinical research
It was agreed that it is of key importance to increase
awareness of quality controls required in preclinical
research: a suggestion was made to include internal
controls for drug experimentation in the form of a
‘standard’ drug for which the effect is already known.
However, it was also recognized that this may not
always be possible, due to restrictions of local ethical
committees.
To increase the number of available TREAT-NMD
SOPs, it was suggested that a Bio-NMD SOP be
added for mouse serum sample collection and stor-
age, to include the influence of freezing/thawing
and other factors, and conditions in the assessment
of biomarkers. For DMD dogs, the development of
additional SOPs on functional tests like the 6MWT,
gait analysis, accelerometry, respiratory and cardiac
assessments was suggested.
It was also proposed to establish a curated database
of natural history for mdx mice, to allow for meta-
analysis of main mouse outcomes. The database
should start by collecting data for mdx (considering
both C57BL/10ScSnJ and C57BL/6J backgrounds;
other genetic backgrounds could be added in a later
phase) and mdx-utrn-/- mice. Key parameters to
be measured (and replicated across multiple labs)
include: survival (mdx-utrn-/- only), creatine kinase
levels, grip strength, hanging test, locomotion assess-
ment, force contraction, histology (quantification of
centrally nucleated fibers, muscle fiber size, and
fibrosis) as well as cardiac function. Measurement
units, devices, mouse ages, gender, origins (commer-
cial or in-house breeding) and sample sizes need be
specified. Costs and personnel were briefly discussed
and it was decided to explore funding opportunities.
Work on collecting and collating data for this purpose
has commenced.
Establish rules to accept SOPs submitted
spontaneously to TREAT-NMD
Raffaella Willmann informed the group that the
contact point for all requests about SOPs has been
transferred to the TREAT-NMD secretariat and that
a clear list for the acceptance procedure needs to be
set.
The discussion suggested the following criteria
need to be employed: use of a relevant model (DMD:
mdx, GRMD/CXMDJ; SMA: all); data should have
been reproduced several times in the originator lab-
oratory and independently validated in at least two
additional laboratories; information on sample size
calculation for power analysis needs to be included;
data on untreated animals (wild type and relevant
disease model) should be reported for reference.
If criteria are met, the secretariat should contact
the core committee (Miranda Grounds, Kanneboyina
Nagaraju or Annemieke Aartsma-Rus for DMD
mouse model assessments, Tom Gillingwater for
SMA mouse model assessments) to nominate 2–3
adequate peer reviewers. Timeline: 2 weeks to check
criteria, 1 week to identify reviewers, negotiation of
6–8 weeks to review protocol. Peer reviewers will
appear on the SOP.
Organization of a stakeholder meeting to raise
awareness of preclinical study quality in
neuromuscular disease research
All participants agreed that the responsibility for
increasing quality and reproducibility in preclini-
cal research data cannot fall entirely on individual
researchers. Funding organizations with no peer
review, sometimes support studies without consid-
ering an appropriate project selection based on
feasibility and on a strong rationale. Journals could
play a key role by requiring stronger guidelines for
publishing preclinical studies that aim at translation
to clinical trials. The issue of extrapolation of mouse
data to human outcomes should be discussed as well,
especially for nutrition, standards of care, fatigue,
strength, locomotion, and BMI through a retrospec-
tive evaluation of existing clinical data and animal
model data. In addition, the need for preclinical
research to connect and interact with the requirements
of clinical studies was considered an important issue
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to address. Input on these matters is required from
clinicians, academic researchers, funding agencies,
Journal editors, and industry, as well as patient groups
and representatives from regulatory agencies. It was
decided to apply for a European Neuromuscular Cen-
ter (ENMC) Workshop to address these important
topics in a subsequent Workshop. This was achieved
with a Workshop held in 2017 (see below).
CONCLUSIONS AND DELIVERABLES
The scope of this Schiphol workshop was to revise
and review the efforts undertaken by the TREAT-
NMD Alliance to improve the quality of preclinical
studies for DMD and SMA, and to suggest feasible
next steps for further developments.
Since the Workshop, the following main deliver-
ables that have been achieved to date are (1) the
establishment of a curated database of natural his-
tory for mdx, which allows for meta-analysis of main
mouse outcomes, and (2) Guidelines and rules are
now in place for the creation and submission of
future SOPs. Finally, (3) a subsequent, larger ENMC
Workshop was organized and took place in February
2017 in order to discuss preclinical study quality, with
representatives from academic and clinical research,
industry, patients, funding agencies, journals and
regulatory agencies (Report manuscript in press).
Initiatives from this Workshop which are still pend-
ing are: finalisation of a SOP on serum collection
for biomarker analyses in DMD mouse models, gen-
eration of more SOPs for DMD dog models, and
agreements on standards of reporting for SMA pre-
clinical research.
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